Clinical Trial

A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung

Study acronym: LCNEC-ALPINE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II clinical trial evaluates the efficacy, safety and tolerability of Atezolizumab in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-07-20; most recent amendment 2026-04-13.
Status change: Recruiting → Active, Not Recruiting 2025-01-17
Trial Details
NCT Number NCT05470595
Lead Sponsor Technische Universität Dresden
Collaborators: Roche Pharma AG
Conditions Large Cell Neuroendocrine Carcinoma of the Lung
Enrollment 67 participants
Start Date 2022-01-18
Primary Completion 2028-01-31 (estimated)
Study Completion 2029-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-15